Octapharma Pharmazeutika Produktionsges.m.b.H.
Oberlaaer Straße 235
Vienna is the location of Octapharma's main production facilities also housing the Research & Development Department and its laboratories. In 1989, the Vienna plant an area comprising approx. 27,000 m2 - was acquired by Octapharma. At that time parts of the site were no more than an empty shell but through heavy investments a modern pharmaceutical plant, meeting all national and international GMP-standards, was built and became Octapharma's main production and R&D facilities in the Nineties.
To meet the rising demand as well as the requirements of new Octapharma products, new production units, such as the Octaplas line, were installed, the fractionation capacity significantly increased, and new production technologies introduced.
Over the years extensions were made, such as a new warehouse, additional plasma storage areas, an administrative building and a new laboratory wing to accommodate both the growing number of staff as well as the increased volumes of production materials.
Vienna Site Development
In 1989, Octapharma acquired the Vienna plant when parts of the site were no more than an empty shell. Through heavy investment, the facility has been converted into one of the most modern plasma plants in the world. The entire site was reviewed and approved for meeting GMP-standards.
In 1993, the production line for the then newly introduced octaplas® was installed and a new warehouse was added, along with a storage area for hazardous materials outside the plant area. At the same time, a new administrative area was built to improve working conditions.
In 1997, a new power supply, an on-site distillation plant and an extensive plasma storage facility were completed.
In 2000, a new laboratory wing for the Research & Development department was created and the capacity for basic fractionation has been extended.
In 2001, the entire site was reviewed and modernised to maintain ever more demanding GMP-standards. With the implementation of a Total Quality System and additional investments in new technologies for production, quality control, utilities and IT, the plant now meets FDA standards.
In 2002 the laboratories for Quality Control have been extended to enable independent on-site testing in accordance with international regulations. Furthermore, a considerable increase in staff required the construction of a new administrative building with additional office space. In addition adjacent land could be purchased to enable further development of the site.
In 2003, the labelling and packaging department was extended. On top of this extension a new rooftop cafeteria for all employees provides a comfortable atmosphere and a great view across the southern parts of Vienna.
In 2004, the plant had been further extended by adding a building to house production suites for purification of proteins, additional freeze driers and new filling lines: The first of these lines for large volume parenterals in isolator technology went into operation already in 2005.
Also in 2004, octagam®, the group's intravenous Immunoglobulin, was licensed with the FDA in USA and since then the Vienna facility manufactures the product to be distributed in the US market.
In 2005 the successful market launch of a new von Willebrand Factor VIII preparation, further increases product output and leads to new investment activities thus securing the position of Vienna as important part of the Octapharma group.
In 2006, additional land adjacent to the existing facility could be purchased, increasing the area by 22.000 m2 to a total of 55.000 m2. With this, intensive planning for various investment projects to reach a final fractionation capacity of 1,700.000 litres of plasma has been initiated. Furthermore, Human Albumin was also licensed with the FDA, thus strengthening Octapharma's market position in the USA.
In 2007, a building to house the utilities and an ethanol re-distillation plant as well as workshops for Engineering had been constructed on the land purchased in 2002. With this, the plant has sized its utilities to be prepared for the capacity increase in Fractionation. The buildings on the land acquired in 2006 have been adapted are used for offices and material storage.